Two key 12-month studies showed positive effects on exacerbation rates and pulmonary function . Two supporting six – month studies also confirmed the efficacy of Daxas when used with standard bronchodilator treatments used. The full data from all four studies are to be published in 2009.. In May 2009 Announces FDA filing of Daxas in COPDNycomed announced the submission of a New Drug Application with the U.S. Food and Drug Administration for Daxa as a once-daily oral treatment for patients with symptomatic COPD.
In May 2009, Nycomed also completed the submission of a Marketing Authorisation Application to the European Medicines Agency for Daxas as a once-daily oral treatment for patients with symptomatic COPD. The submission is currently under review by the regulatory authorities. – H kan rklund Year, Chief Executive Officer of Nycomed, said: With its novel mechanism of action, wHO an important new approach for the treatment of COPD – a disease that is expected to become the third leading cause of death worldwide by 2030. The FDA submission , following the submission of Daxas to the EMEA May, is another important step for Daxas in the key U.S. Market. Discussions with potential U.S. Commercialization partners are already well advanced. .The automated interpretive summary offers accurate and useful information about BP mean, overnight dip proportion, and authorities to White skirt ‘s syndrome.. SunTech Medical for the Oscar 2 24-hour ambulatory sphygmomanometer has scored an A / A rating by the British Hypertension Society protocol as the April 2007 issue by Blood Pressure Monitoring , European Society of Hypertension International Protocol noninvasive bloodon for promotion of medical Instrumentation SP10.
Three arms been at random from 403 HCV genotype type 1 patients – previously failed treatment of partial / non-responders or a relapse suffering selected:.